Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …

Cardiovascular disease (CVD) is the leading cause of mortality in people with type 2
diabetes mellitus (T2DM), yet a significant proportion of the disease burden cannot be …

Glucagon-like peptide-1, produced predominantly in enteroendocrine cells, controls glucose
metabolism and energy homeostasis through regulation of islet hormone secretion …

The incretin hormone Glucagon-Like Peptide-1 (GLP-1) is best known for its “incretin effect”
in restoring glucose homeostasis in diabetics, however, it is now apparent that it has a …

The glucagon-like peptide (GLP)-1 receptor (GLP-1R) is a class BG protein–coupled
receptor (GPCR) that mediates the action of GLP-1, a peptide hormone secreted from three …

Abstract Glucagon-like peptide-1 (7–36) amide (GLP-1) is a secreted peptide that acts as a
key determinant of blood glucose homeostasis by virtue of its abilities to slow gastric …

The World Health Organisation has estimated that by 2015 approximately 2.3 billion adults
will be overweight and more than 700 million obese. Obesity is associated with an increased …

Obesity is one of the major challenges to human health worldwide; however, there are
currently no effective pharmacological interventions for obesity. Recent studies have …

Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular
disease. The strong connection between the severity of hyperglycaemia, metabolic changes …

Glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1)
are the two primary incretin hormones secreted from the intestine on ingestion of various …